98%
921
2 minutes
20
Parkinson's disease (PD) is a complex neurological disorder characterized by dopaminergic neuron degeneration, leading to diverse motor and non-motor impairments. This variability complicates accurate progression modelling and early-stage prediction. Traditional classification methods based on clinical symptoms are often limited by disease heterogeneity. This study introduces an graph-based interpretable personalized progression method, utilizing data from the Parkinson's Progression Markers Initiative (PPMI) and Stroke Parkinson's Disease Biomarker Program (PDBP). Our approach integrates multimodal inter-individual and intra-individual data, including clinical assessments, MRI, and genetic information to make multi-dimension predictions. Validated using the PDBP dataset from 12 to 36 months, our AdaMedGraph method demonstrated strong performance, achieving AUC values of 0.748 and 0.714 for the 12-month Hoehn and Yahr Scale and Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III on the PPMI test set. Ablation analysis reveals the importance of baseline clinical assessment predictors. This novel framework improves personalized care and offers insights into unique disease trajectories in PD patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609293 | PMC |
http://dx.doi.org/10.1038/s41531-024-00832-w | DOI Listing |
J Neural Transm (Vienna)
September 2025
Parkinson's Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, SE5 9RS, UK.
Parkinson's disease patients are at increased risk of road traffic and car accidents and those with excessive daytime sleepiness are specially susceptible. Abnormal scores on the Epworth Sleepiness Scale predicts risk for driving-related somnolence which may cause road traffic accidents in driving patients as many such patients declare dozing of while in a car. Our study estimates that over 40% of patients with daytime somnolence have risks of dozing off in a car.
View Article and Find Full Text PDFAm J Geriatr Psychiatry
August 2025
Department of Psychiatry (MLO, SEC, JZ, KS), Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Neuroimmunology Research Group (KS), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Psychiatric Program of the Netherlands Brain Bank (KS), Ne
Parkinson's disease (PD) is characterized by two neurobiological markers: pathological α-synuclein and/or a dopaminergic deficit. Depression is common in PD, and may precede motor signs, particularly in late-onset depression (LOD). We conducted two systematic reviews and a meta-analysis to examine the relationship between depression and PD development.
View Article and Find Full Text PDFParkinsonism Relat Disord
September 2025
Graduate Program in Medical Sciences, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Department of Neurology, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil. Electronic address:
Pract Neurol
September 2025
Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Methods Cell Biol
September 2025
Histology and Cell Biology Department, School of Medicine, Complutense University of Madrid, Madrid, Spain. Electronic address:
Parkinson disease (PD) is the second most prevalent neurodegenerative disorder globally, trailing only Alzheimer´s disease. It currently affects nearly 3 % of individuals aged 65 and above. The disease is characterized by the progressive loss of dopaminergic neurons accompanied by a chronic neuroinflammatory process, which is responsible for both motor symptoms (tremor, rigidity, bradykinesia) and non-motor symptoms (depression, dysphagia, anxiety, constipation, and anosmia).
View Article and Find Full Text PDF